Hepatitis B Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Laboratories, Qilu Pharma, Golden Biotechnology, Sunshine Lake Pharma, Ascenta

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hepatitis B Virus pipeline constitutes 80+ key companies continuously working towards developing 90+ Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hepatitis B Virus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hepatitis B Virus Market.

The Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hepatitis B Virus Pipeline Report: https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hepatitis B Virus treatment therapies with a considerable amount of success over the years.
• Hepatitis B Virus companies working in the treatment market are Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others, are developing therapies for the Hepatitis B Virus treatment
• Emerging Hepatitis B Virus therapies in the different phases of clinical trials are- PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others are expected to have a significant impact on the Hepatitis B Virus market in the coming years.
• In October 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to manage diseases, has announced the completion of enrollment for two clinical trials: HBV003, a Phase 2b trial of VTP-300 in adults with chronic hepatitis B (CHB), and PCA001, a Phase 1 trial of VTP-850 in men with increasing prostate-specific antigen (PSA) levels following definitive local therapy for prostate cancer (biochemical recurrence).

Hepatitis B Virus Overview
Hepatitis B virus (HBV) is a viral infection that attacks the liver and can cause both acute and chronic diseases. It is transmitted through contact with infected blood, semen, or other body fluids, often through unprotected sex, sharing needles, or from mother to child during childbirth. Acute HBV infection may cause symptoms like fatigue, jaundice, abdominal pain, and nausea, while chronic infection can lead to serious liver problems, including cirrhosis and liver cancer. Vaccination is the most effective way to prevent HBV, and antiviral medications are available to manage chronic infections.

Get a Free Sample PDF Report to know more about Hepatitis B Virus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:
• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• GSK3965193: GSK
• DF 006: Drug Farm
• AB 729: Arbutus bio
• RG6346: Dicerna Pharmaceuticals
• RG7854: Roche
• Bepirovirsen: GSK
• Pradefovir: Ligand Pharmaceuticals
• Pradefovir: Ligand Pharmaceuticals
• DA 2802: Dong-A ST Co.
• VIR-2218: Vir Biotechnology
• AB-729: Arbutus Biopharma

Hepatitis B Virus Route of Administration
Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hepatitis B Virus Molecule Type
Hepatitis B Virus Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Hepatitis B Virus Pipeline Therapeutics Assessment
• Hepatitis B Virus Assessment by Product Type
• Hepatitis B Virus By Stage and Product Type
• Hepatitis B Virus Assessment by Route of Administration
• Hepatitis B Virus By Stage and Route of Administration
• Hepatitis B Virus Assessment by Molecule Type
• Hepatitis B Virus by Stage and Molecule Type

DelveInsight's Hepatitis B Virus Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hepatitis B Virus product details are provided in the report. Download the Hepatitis B Virus pipeline report to learn more about the emerging Hepatitis B Virus therapies at:
https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hepatitis B Virus Therapeutics Market include:
Key companies developing therapies for Hepatitis B Virus are - Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, and others.

Hepatitis B Virus Pipeline Analysis:
The Hepatitis B Virus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis B Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis B Virus Treatment.
• Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis B Virus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hepatitis B Virus drugs and therapies-
https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatitis B Virus Pipeline Market Drivers
• High prevalence of chronic HBV infection, increasing Research and development in Chronic Hepatitis B are some of the important factors that are fueling the Hepatitis B Virus Market.

Hepatitis B Virus Pipeline Market Barriers
• However, high cost of treatment, limited access to the diagnosis of hepatitis B and other factors are creating obstacles in the Hepatitis B Virus Market growth.

Scope of Hepatitis B Virus Pipeline Drug Insight
• Coverage: Global
• Key Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others
• Key Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others
• Hepatitis B Virus Therapeutic Assessment: Hepatitis B Virus current marketed and Hepatitis B Virus emerging therapies
• Hepatitis B Virus Market Dynamics: Hepatitis B Virus market drivers and Hepatitis B Virus market barriers

Request for Sample PDF Report for Hepatitis B Virus Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hepatitis B Virus Report Introduction
2. Hepatitis B Virus Executive Summary
3. Hepatitis B Virus Overview
4. Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment
5. Hepatitis B Virus Pipeline Therapeutics
6. Hepatitis B Virus Late Stage Products (Phase II/III)
7. Hepatitis B Virus Mid Stage Products (Phase II)
8. Hepatitis B Virus Early Stage Products (Phase I)
9. Hepatitis B Virus Preclinical Stage Products
10. Hepatitis B Virus Therapeutics Assessment
11. Hepatitis B Virus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hepatitis B Virus Key Companies
14. Hepatitis B Virus Key Products
15. Hepatitis B Virus Unmet Needs
16 . Hepatitis B Virus Market Drivers and Barriers
17. Hepatitis B Virus Future Perspectives and Conclusion
18. Hepatitis B Virus Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Hepatitis B Virus Epidemiology https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hepatitis B Virus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.